Skip to main content
$0.160 -0.005 (-3.03%)

High

$0.16

Low

$0.16

Trades

13

Turnover

$11,013

Volume

68,980
30 June 2023 at 12:18pm
If you were already registered, log in here.

Short Interest

ASIC data, 1 Nov 2023

% Shorted

0.00%
vs 0.00% prior report

Most Shorted Rank

657th
of 717 shorted ASX stocks

Peak Short

0.96%
Mar 2020

Days to Cover

0.0
at 50d avg vol
Subject
KZA Ann: Change in substantial holding

KZA Ann: Cleansing notice

KZA Ann: Application for quotation of securities - KZA

KZA Ann: Kazia presentation on paxalisib for childhood brain cancer

KZA Ann: Change in substantial holding

KZA Ann: Cleansing Notice

KZA Ann: Application for quotation of securities - KZA

KZA Ann: Kazia's paxalisib gains ODD for ATRT

KZA Ann: FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT

KZA Ann: Kazia paxalisib preclinical DIPG data released at IPSNO

KZA Ann: Cleansing notice

KZA Ann: Application for quotation of securities - KZA

KZA Ann: Kazia's Alliance study progresses to expansion phase

KZA Ann: Cleansing notice

KZA Ann: Proposed issue of securities - KZA

KZA Ann: Kazia presents final PII data at ASCO

KZA Ann: Application for quotation of securities - KZA

KZA Ann: Proposed issue of securities - KZA

KZA Ann: GBM Agile opens to paxalisib in Europe

KZA Ann: Cleansing notice

KZA Ann: Application for quotation of securities - KZA

KZA Ann: Notification regarding unquoted securities - KZA

KZA Ann: Kazia marks DIPG Awareness Day

KZA Ann: Application for quotation of securities - KZA

KZA Ann: Cleansing notice

KZA Ann: Notification regarding unquoted securities - KZA

KZA Ann: Application for quotation of securities - KZA

KZA Ann: Update - Proposed issue of securities - KZA

KZA Ann: Kazia to present at ASCO

KZA Ann: Quarterly Activities/Appendix 4C Cash Flow Report

KZA Ann: Proposed issue of securities - KZA

KZA Ann: Kazia establishes ATM program

KZA Ann: Proposed issue of securities - KZA

KZA Ann: Kazia's paxalisib Phase II trial achieves completion

KZA Ann: Kazia presents preclinical data for paxalisib at AACR

KZA Ann: Kazia presents on EVT801 at AACR

KZA Ann: Kazia response to SEC comments letter

KZA Ann: Kazia to present at two conferences

KZA Ann: Change in substantial holding

KZA Ann: First patient into Cornell keto study

KZA Ann: Kazia Half Year Accounts and Appx 4D

KZA Ann: Notification regarding unquoted securities - KZA

KZA Ann: Quarterly Activities/Appendix 4C Cash Flow Report

KZA Ann: Kazia Corporate Deck

KZA Ann: Change of Director's Interest Notice

KZA Ann: Change of Director's Interest Notice * 3

KZA Ann: Change in substantial holding

KZA Ann: Issue of shares

KZA Ann: Kazia appoints Karen Krumeich as CFO

KZA Ann: Kazia releases final data from P2 paxalisib trial

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX
S88
MAV
CX8
MTX $12m raise
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS